{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"title":"CR achieved"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"title":"CR achieved with first course of induction"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"title":"CR + CRp achieved"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"title":"CR achieved with no AHD"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"title":"CR achieved with AHD"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"title":"CR + CRp achieved with AHD"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"title":"CR achieved with FLT3 positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"CR achieved with favorable risk cytogenetics"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"title":"CR achieved with intermediate risk cytogenetics"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"title":"CR + CRp achieved with intermediate risk cyto."},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"CR achieved with unfavorable risk cytogenetics"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"CR + CRp achieved with unfavorable risk cyto."}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"description":"With 50 patients, the rates of these endpoints will be estimated with a standard error of 5 to 7 percentage points, depending on the observed rates. Complete remission is defined as less than 5% blast cells present in the bone marrow and count recovery (absolute neutrophil count greater than 1000/microL and platelet count greater than 100,000/microL). Complete remission with incomplete recovery of counts is defined as less than 5% blast cells present in the bone marrow without compete count recovery (absolute neutrophil count less than 1000/microL and platelet count less than 100,000/microL).","groups":[{"description":"INDUCTION THERAPY: Patients receive filgrastim SC daily beginning the day prior to chemotherapy and continuing until blood counts recover. Patients receive clofarabine IV over 1 hour followed by cytarabine IV over 2 hours daily for 5 days.\n\nCONSOLIDATION THERAPY: Patients receive filgrastim SC daily for 5 days beginning the day prior to chemotherapy. Patients receive clofarabine IV over 1 hour followed by cytarabine IV over 2 hours daily for 4 days.\n\nTreatment with induction therapy may continue for up to 2 courses and treatment with consolidation therapy may continue for up to 3 courses in the absence of disease progression or unacceptable toxicity.\n\nfilgrastim: Given SC\n\nclofarabine: Given IV\n\ncytarabine: Given IV","id":"OG000","title":"Treatment (Chemotherapy and Colony Stimulating Factor)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"CR achieved with no AHD only applies to those who did not have AHD.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Rates of Complete Remission and Complete Remission With Incomplete Recovery of Counts","type":"PRIMARY","unitOfMeasure":"Participants"}